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Summary 
Superantigens, in association with class II major histocompatibility complex (MHC) molecules, 
activate T cells bearing particular/~ chain variable domains of the T cell receptor (TCR). Unlike 
conventional peptide antigens, superantigens bind as intact proteins to TCR and MHC molecules 
outside their peptide binding sites. To characterize  these interactions at the molecular level, random 
point mutations were generated in the gene encoding toxic shock syndrome toxin 1, a bacterial 
superantigen associated with toxic shock syndrome. Functionally impaired mutants were identified 
based on their lack of murine and human T cell stimulatory activities, and experiments analyzing 
binding  to human  histocompatibility leukocyte antigen-DR  molecules differentiated residues 
involved in MHC from TCR binding. The results showed that the great majority of mutations 
are clustered in two distinct regions of the toxic shock syndrome toxin 1 molecule. The class 
II MHC binding  site is located in the hydrophobic region of the NH2-terminal  domain,  and 
the TCR binding site is primarily in the major central groove of the COOH-terminal domain. 
These studies provide insight into the interactions  necessary for superantigen-mediated  disease 
in humans. 
S 
taphylococcus  aureus  and  group  A  streptococci  secrete a 
number of exotoxins expressing superantigen activity, in- 
cluding  toxic  shock  syndrome  toxin  (TSST)I-1,  staphylo- 
coccal enterotoxins A to E, and streptococcal pyrogenic exo- 
toxins A  and C  (1,  2).  TSST-1  has  been shown to be the 
major cause of toxic shock syndrome (2-4).  The develop- 
ment of this disease appears to be dependent on superantigen- 
induced T  cell stimulation  and consequent systemic release 
of cytokines such as TNF and IL-2 (2, 5). TSST-1 activates 
human T cells bearing/~ chain variable domains (VB)-2, which 
represent '-10% of the total T cell repertoire (5-7), and stim- 
ulation is dependent upon antigen-presenting cells expressing 
HLA-DR molecules (8, 9). Although x-ray crystallographic 
studies have suggested that TSST-1 consists of two separate 
domains (10, 11), the TCR and MHC binding sites have not 
yet been defined.  The present  study used a comprehensive 
mutagenesis of TSST-1 to functionally define these binding 
sites. 
1 Abbreviations used in this palx,'r: SEB, staphylococcal  enterotoxin B; TSST, 
toxic shock syndrome toxin; Vt3, B chain variable domain. 
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Materials and Methods 
Cloning of the Tst-1 Gene from S. Aureus.  Total  genomic DNA 
was extracted from several strains of TSST-l-producing  S. aureus 
(kindly provided by Dr. John James and Dr. Jim Todd, Children's 
Hospital, Denver, CO) using a protocol (12) modified for small 
bacterial cultures.  For cloning,  the wild-type tst-1 gene (13) was 
amplified by PCR using flanking primers A and B shown in Table 
1. Forward primer A anneals to the first seven codons of the ma- 
ture wild-type tst-1 gene of S. aureus. Preceding these codons in 
primer A is an initiation  codon (ATG), a ribosome binding  site 
(GGAGG) and a spacer region (As) for efficient expression in Esch- 
erichia coli (14), along with a KpnI restriction site for cloning. Re- 
verse primer B anneals to the final 10 codons of tst-1 (including 
the ochre stop codon TAA) and also contains an XbaI restriction 
site. After agarose gel electrophoresis and purification by GeneClean 
(Bio 101, Inc., Vista, CA),  the PCR product was digested with 
KpnI and XbaI and cloned into E. coli as described (15). Several 
wild-type clones were sequenced, confirming the published sequence 
(13) as corrected by Lee et al. (16). 
Generation of Mutant TSST-I Proteins.  PCR primers carrying 
random mutations (Table 1) were used to generate mutant TSST-1 
molecules. The primers were synthesized such that, at each posi- 
tion,  the three incorrect  nucleotides were incorporated  at a fre- 
quency of 0.25-1.0% (17). Mutations  were introduced  into tst-1 
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in  This Study 
A  CGG  GGT  ACC  CCG  AAG  GAG  GAA  AAA  AAA  ATG TCT ACA AAC  GAT AAT ATA AAG 
i)  TCT ACA AAC  GAT  AAT  ATA  AAG  GAT  TTG  CTA  GAC  TGG  TAT AGT AGT  GGG  TCT 
2}  GGG  TCT  GAC  ACT  TTT  ACA  AAT  AGT  GAA  GTT  TTA  CAT  AAT  TCC  TTA  GGA  TCT 
3)  C.G.A TCT  ATG  CGT  ATA  AAA  AAC  ACA  GAT  GGC  AGC ATC AGe  CTT  ATA  ATT  TTT 
4)  ATT  TTT  CCG  AGT  CCT  TAT  TAT  AGC  CCT  GCT  TTT ACA AAA  GGG  GAA  AAA  GTT 
5)  AAA  GTT  GAC  TTA  AAC  ACA  AAA  AGA  ACT  AAA  AA.%  AGC  CAA  CAT  ACT  AGC  CJ~A 
6)  AGC  GAA  GGA  ACT  TAT  ATC  CAT  TTC  CAA  ATA  AGT  GGC  GTT  ACA  AAT  ACT  C~A 
'7)  ACT  GAA  AAA  TTA  CCT  ACT  CCA  ATA  GA.%  CTA  CCT  TTA  AAA  GTT  AAG  GTT  CAT 
8)  GTT  CAT  GGT  AAA  GAT  AGC  CCC  TTA  AAG  TAT  TGG  CCA  AAG  TTC  GAT  AAA  AAA 
9)  AAA  AAA  CAA  TTA  "~-CT ATA  TCA  ACT  TTA  GAC  TTT  GAA  ATT  CGT  CAT  CAG  CTA 
i0)  CAG  CTA  ACT  CAA  ATA  CAT  GGA  TTA  TAT  CGT  TCA  AGC  GAT  AAA  ACG  GGT  GGT 
II)  GGT  GGT  TAT  TGG  AAA  ATA  ACA  ATG  AAT  GAC  GGA  TCC  ACA  TAT  CAA  AGT  CAT 
12)  AGT  GAT  TTA  TCT  AAA  AAG  TTT  GAA  TAC  AAT  ACT  GAA  AAA  CCA  CCT  ATA  AAT 
13)  ATA  AAT  ATT  GAT  GAA  ATA  AAA  ACT  ATA  GAA  GCA  GAA  ATT  AAT 
The primers A and B are forward and reverse flanking oligonucleotide 
primers, respectively. The 13 indicated primers, which were randomized 
with incorrect nucleotides as indicated in the text, were used for muta- 
genesis of the entire tst-I gene. Underlined nucleotides represent regions 
of overlap between consecutive primers to ensure mutagenesis at the 
residues. Basepair mismatches near the 3' end of mutagenic primers might 
perturb the primer-template junction and hence not be incorporated into 
the initial PCR product. 
via the "megaprimer" PCR method (18, 19). The first PCK reac- 
tion was performed using I of the 13 mutagenic primers indicated 
in Table I paired with reverse primer B and with the cloned wild- 
type tst-1 gene as template.  After agarose gel electrophoresis  and 
purification, this PCR product (megaprimer) was used directly in 
a second PCR reaction with primer A and tst.1 template to recon- 
struct the full-length gene.  Finally, using gel-purified  full-length 
product, a third PCR reaction was performed with fanking primers 
A  and B to generate sufficient  material  for cloning.  Full-length 
tst-1 genes with mutations were then cloned into either pTZ18R 
or pUC18 plasmids  and transformed into E. coli for production 
and screening  of mutant proteins (15). 
Quantitation of TSST-I.  Individual colonies of E. coli transfor- 
mants harboring mutated tst-1 genes were grown in 96-well plates 
containing 0.2 ml of 2￿  YT liquid medium (15) and carbenicillin. 
The production of recombinant TSST-1 was induced by the addi- 
tion of I mM isopropyl-B-o-thiogalactoside,  and bacterial  lysates 
were prepared  as described  (17). To measure  the amount of toxin 
in each lysate, a sandwich ELISA was developed using mAbs to 
TSST-1, produced by standard methods from BALB/c mice im- 
munized multiple times with TSST-1. The properties  of these anti- 
bodies will be described in detail elsewhere (Shimonkevitz, R. S., 
E. Boen, S. Malmstrom, E. Brown, J. M. Hurley,  B. Kotzin, and 
M. Matsumura,  manuscript submitted for publication). Two of  these 
mAbs specific for different sites on TSST-1 were adsorbed overnight 
to microtiter plates, each at a concentration of 1.0 #g/ml in PBS. 
After washing to remove unbound antibody, lysates or known con- 
centrations of TSST-1 were added to the microtiter wells and in- 
cubated for 2 h. After a second wash, a horseradish peroxidase-con- 
jugated rabbit anti-TSST-1 (Toxin Technology, Sarasota, FL) was 
used as a secondary reagent to detect bound toxin. The color reac- 
tion was developed using o-phenylene-diamine  and detected  using 
a microplate ELISA reader. 
Purification of Mutant  TSST-1 Proteins.  Typically, 1 liter  of E. 
coli was grown overnight and the production of TSST-1 was in- 
duced for 24 h as described above. Cells were harvested by centrifu- 
gation, suspended in 20 ml of 10-mM Tris-HC1/1-mM EDTA buffer, 
pH 7.4, and disrupted by uhrasonication. The bacterial extract was 
centrifuged and dialyzed overnight against 10 mM potassium phos- 
phate buffer, pH 6.1. The TSST-1 protein was then purified by HPI.C 
using a cation exchange column (SP-5-PW; Bio-Rad Laboratories, 
Hercules,  CA) with a linear  NaCI gradient from 0 to 500 mM 
in  10 mM potassium phosphate buffer,  pH 6.1.  The wild-type 
TSST-1 was  eluted  at  m120  mM  NaC1.  This  method  yielded 
"~10 mg of purified TSST-1 protein/liter of bacterial culture.  The 
wild-type and mutant TSST-1 proteins prepared  by this  method 
were judged to be >95% pure by analysis on gels after SDS-PAGE. 
Assays for  T  Cell Stimulatory Activity.  Bacterial  lysates were 
screened for superantigen activity by stimulation of a murine T 
cell hybridoma as described  (17). Since murine T cells responding 
to TSST-1 are contained within the subset expressing VB15, a hy- 
bridoma cell line expressing  VB15 (KOX 15-4.95) was used as re- 
sponder cells. Various dilutions of lysate in 0.2 ml culture medium 
(RPMI 1640 or IMDM containing 10% fetal bovine serum, 2 mM 
L-glutamine,  2 mM pyruvate,  10 mM Hepes,  50 U/ml penicillin, 
and 50 mg/ml streptomycin) were added to microtiter culture wells 
containing  ,'ol  x  10  s T  hybridoma cells and  5  x  104  HLA- 
DR-expressing antigen-presenting cells (either  LG2, a human B 
lymphoma cell line homozygous for DR1, or Raji-DR, described 
below). T cell stimulation was assayed after the overnight release 
of IL-2 using the IL-2-dependent HT-2 cell line bioassay. 
Human PBL were prepared by Ficoll-Hypaque centrifugation, 
and 1  x  105 ceils were added to microtiter wells containing var- 
ious dilutions of the wild-type or mutant TSST-1 proteins  in 0.2 
ml culture medium (described above). Cultures were incubated at 
37~  for 3 d, pulsed overnight with 0.5/zCi tritiated thymidine, 
and harvested.  Cellular proliferation  was measured by the amount 
of incorporated radioactivity as quantitated with a beta scintilla- 
tion counter. 
In selected experiments,  stimulation of a human V32 + cell line 
was also studied.  Human PBL were stained for V/32 and CD4 as 
described  (20) and sorted on a cytofluorograph. Double-positive 
cells were expanded  by culture at 2  x  10S/ml in the presence of 
106 unseparated  autologous PBL (previously  irradiated  to 4,000 
rad) and 1/~g/ml PHA-P (Murex Diagnostics, Ltd., Dartford, UK). 
After 5 d of culture, PHA was washed out, and IL-2 was added 
for an additional  10 d before using the ceils in a stimulation assay. 
For response  to wild-type and mutant TSST-1 proteins,  V32 + T 
cells were cultured at 5  x  104 cells per well in 0.2 ml of the cul- 
ture medium described  above with  1  x  l0  s LG2 cells. 
Class H MHC Binding Assay.  Mutant proteins were tested for 
binding to class II MHC using the Raji-DR cell line (American 
Type Culture Collection, Rockville, MD), which expresses a high 
and homogeneous level of cell surface HLA-DR detected  by im- 
munofluorescence.  HPLC-purified wild-type and mutant TSST-1 
protein were biotinylated, and various concentrations were incubated 
in the presence of 5  x  105 Raft cells on ice for 2 h in HBSS con- 
taining 0.1% BSA and 0.1% sodium azide. After washing, bound 
TSST-1 was detected  by incubation with PE-avidin,  and fluores- 
cence intensity was analyzed on a cytofluorograph. At least 2  x 
104 viable cells were evaluated for binding and compared to cells 
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manner. 
Results and Discussion 
To identify the class II MHC and TCK binding sites on 
TSST-1, we generated random mutations throughout the en- 
tire 194-residue mature protein. The initial screening for mu- 
tant  proteins  was based on the ability of a murine  VB15- 
expressing T  cell hybridoma to secrete IL-2 in response to 
the wild-type recombinant TSST-1 expressed in E. coli. Ly- 
sates of individual bacterial clones that failed to stimulate IL-2 
production  were then  screened by ELISA for the presence 
of toxin.  Clones that  failed to produce toxin or produced 
toxin at <25% of the wild-type levels were eliminated from 
further  analysis. 
The frequency of mutations resulting in nonstimulatory 
toxins varied greatly in different regions of the molecule (Table 
2).  Two functionally important  regions were revealed.  The 
first region, defined by libraries 1-3, corresponds to residues 
1-47 of the mature TSST-1 protein.  Of 846 transformants 
screened within this region, 35 clones (4.1%) failed to stimulate 
the murine T  cell hybridoma. The second region comprises 
residues 91-152 (libraries  7-10).  Here,  155 of 1,646 clones 
(9.4%)  were negative for routine T  cell hybridoma activa- 
tion. We found no mutants affecting T  cell stimulation be- 
tween  residues  46  and  92  and  only  one mutant  between 
residues  151 and  194. 
Clones of interest were analyzed by DNA sequencing to 
identify mutations and then tested for their capability to stimu- 
late human PBL (Table 3). Since TSST-1 stimulates human 
V/~2 + T cells, many of the mutants were also tested against 
a human V~2 + T cell line with results identical to those ob- 
tained with human PBL (data not shown). Although many 
mutants that were negative in the murine T cell hybridoma 
stimulation assay showed partial to full activity with human 
responding PBL, several of the mutant toxins were completely 
devoid of human T cell stimulatory activity. These included 
mutants with amino acid substitutions of Tyr13 ~  Leu and 
Set15 ~  Trp (designated Y13L/S15W), G16V,  G31S/S32P, 
all mutants at residues H135 and L137V,  and several at res- 
idue Q139. 
The differences in murine and human T  cell stimulation 
by certain TSST-1 mutants may reflect the extensive amino 
acid polymorphism between the human Vfl2 and murine Vf115 
TCR (5) and/or  differences in the two assay systems used 
to measure T  cell proliferation.  A  similar observation was 
made for a number of staphylococcal enterotoxin B (SEB) 
mutants  that failed to stimulate any murine T  cell hybrid- 
omas (17) but strongly stimulated human T  cells (Kappler, 
J. W., and B. L. Kotzin, unpublished work). The structural 
similarities between murine VB15 and human VB2 that allow 
subsets expressing  these V~  to be selectively targeted  by 
TSST-1  are  not currently  known. 
To further characterize  the mutations that abolished human 
PBL stimulatory activity and to dissect the effects of the mu- 
tations on TCR and MHC binding, several mutant proteins 
of interest  (Y13L/S15W,  G16V,  I45V,  G31S/S32P, T128S/ 
V88A, H135Q, H135R, L137V,  Q139K, and Q139P) were 
purified by ion-exchange HPLC. A quantitative proliferation 
assay of the purified mutant toxins with responding human 
PBL revealed that all of these mutants were 104-106-fold less 
active than the wild-type TSST-1 (Fig.  1 A), except for I45V, 
which showed 100-fold decreased activity (Fig. 1 B). Interest- 
ingly, even very conservative side-chain changes such as G16V, 
H135Q, and L137V in TSST-1 dramatically decreased its T 
cell-stimulatory  activity. 
Table  2.  Frequency of Mutant  TSST-1  Proteins Unable to Stimulate Murine  VflI5 + T  Cells 
Library  TSST-1 residues 
number  subject to mutation  Murine  VB15 stimulation  Percentage 
Functwnal~  defective/to~l  studied 
1  1-17  10/282  3.5 
2  16-32  17/282  6.0 
3  31-47  8/282  2.8 
4  46-62  0/94  0.0 
5  61-77  0/94  0.0 
6  76-92  0/60  0.0 
7  91-107  6/282  2.1 
8  106-122  7/282  2.5 
9  121-137  35/429  8.2 
10  136-152  107/653  16.4 
11  151-167  0/94  0.0 
12  166-182  1/107  0.9 
13  181-194  0/35  0.0 
2231  Hurley  et al. Table  3.  Functional  Effects of TSST-I  Mutations 
Murine VB15  Stimulation of  Binding  to 
nonstimulatory  mutants  human  PBL"  HLA-DR* 
L10Q/DllV  +  +  +  + 
Y13L/S15W  -  +  +  +  + 
S14I  +  + 
S15G  +  +  +  + 
G16V  -  +  +  +  + 
T21R  +  +  +  +  +  +  +  + 
G31S/S32P  -  - 
I45V  +  +  +  +  +  + 
P97L/L102V  +  +  +  + 
L102S  +  +  +  + 
Lll3F/Kll4T  +  +  +  + 
Wll6R,  S  +  +  + 
S127F  + 
T128S/V88AS  +  +  +  + 
F131I,  L,  V,  Y  ++++  ++++  (F131Y) 
E132A,  G,  I,  P,  R,  V,  W  +  +  (E132W),  +  +  +  + 
E132A/Q136L  + +  + + + + 
R134L  + 
H135A,  D,  I,  Q,  R  -  +  +  +  +  (H135Q,  R) 
Q136R  +  +  +  +  +  +  + 
L137V  -  +  +  +  + 
T138I  +  +  +  +  + 
Q139E,  H,  K,  L,  P,  R.  ++,  -  (Q139K,  P)  ++++  (Q139K,  P) 
Q139E/L143S  -  +  +  +  + 
Q139E/S147R  + 
Q139L/Y144F  -  +  +  +  + 
Q139L/Y144N  + 
I140K,  R.,  T,  V  ++++  ++++  (I140R,  T) 
H141D,  L,  N,  P,  R,  Y  +  +++  ++++  (H141N) 
H141L/S147G  +  +  +  + 
R145H,  P,  S  +  +  +  +  +  +  +  +  (R145H) 
T150P  +  +  +  + 
All mutant proteins  listed here,  except for mutations at residues 132, failed to stimulate  the murine V315 T cell hybridoma  yet produced  wild-type 
levels of TSST-1 proteins  as determined  by ELISA. Mutant proteins  with more than two amino acid substitutions  were eliminated  from the table. 
*Toxin concentrations ranging from 2.5 pg to 250 ng/ml were tested. Data from the 2.5-ng/ml dose (see Fig. 1) are presented as:  + + + +, 75-100%; 
+ + +,  50-75%;  + +,  25-50%;  +,  10-25%;  and  -,  <10%  of the response to wild-type toxin. 
tToxin concentrations  from 0.1  ng to  I00/~g/ml were tested,  with data  obtained  using the 0.1/~g/ml dose presented  as:  + + +  +,  75-100%; 
+ + +, 50-75%;  + +, 25-50%;  +,  10-25%; and  -,  <10%  of the binding obtained  using  wild type TSST-1.  Blank  spaces indicate  that  those 
mutants  were not tested  for binding to HLA-DR.. 
SAlthough  only residues  121-137  were targeted  for mutagenesis,  a second mutation  (V88A) was  found by DNA sequencing,  presumably  due to 
a PCR error. 
HLA-DR  binding  studies  using  biotinylated  TSST-1 
directly demonstrated that the G3LS/S32P mutations markedly 
diminished class II MHC  binding,  whereas the I45V muta- 
tion  had  only  a  slight  effect  (Fig.  2).  The  residual  MHC 
binding  of the G31S/S32P  mutant  may account  for its re- 
sidual T  cell-stimulatory activity at high concentration  on 
human  PBL  (Fig.  1  B).  To  dissect  the  effect of mutations 
at residues 31  and 32  on MHC  binding,  single amino  acid 
mutants G31S and $32P were generated. The former mutant 
stimulated human  PBL  similarly to  the wild-type TSST-1, 
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Figure  1.  Proliferative response of human PBL to HPLC-purified mu- 
tant and wild-type TSST-1 proteins. Stimulation assays were performed 
as described in Materials and Methods. (A) Comparison of mutants that 
affect TCR. binding (except for G31S/S32P) -O--, Y13L/S15W; -A-, 
G16V; -~-,  G31S/S32P; -l-,  T128S/V88A;  []  ,  H135Q;  -C]-, 
H135E;  -O-,  L137V;-x--, Q139K;  ~-  ,  Q139P; -&-, wild-type 
ffSST-1. (B) Comparison of mutants that affect MHC binding. -O-, 
G31S; -O-,  $32P; -~,  G31S/S32P;  -V-,  145V; -&--;  wild-type 
rTSST-1. 
whereas the latter was 104-fold  less active than the wild-type 
protein (Fig.  1 B).  Likewise, binding experiments showed 
that $32P was impaired in HLA-DR binding by four orders 
of magnitude (Fig. 2), whereas G31S showed little difference 
from wild type (data not shown). Thus, residue 32 accounts 
for most, but not all, of the impaired interaction with class 
II MHC observed with the double mutant. 
Fig.  3 illustrates  the locations on the three-dimensional 
structure of TSST-1 (11) of mutations that had the greatest 
effect on human T cell-stimulatory activity (see mutants in- 
dicated as negative for human PBL-stimulatory activity in 
Table 3). These mutations are unambiguously  clustered within 
two sites: a TCR binding site comprising both the proximal 
NH2-  and COOH-terminal domains (residues  13-16  and 
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Figure 2.  The binding  of G31S/S32P, $32P, I45V, and wild-type TSST-1 
proteins to Raji cells that express class II MHC on the cell surface. A mu- 
tant Raft cell line, which does not express class II MHC, demonstrated 
undetectable binding of the wild-type TSST-1 at concentrations  as high 
as 100/~g/ml  (data not shown). In the experiment shown, binding was 
detected using biotinylated  mutant and wild-type TSST-1 proteins  and 
streptavidin-PE as secondary reagent.  In separate experiments, identical 
results were obtained using unlabeled toxins and a biotinylated anti-TSST-1 
mAb as detecting reagent (data not shown). Presented data show the per- 
centage of cells staining positively over background controls. In addition, 
fluorescence intensity, assessed by the increase in mean channd fluores- 
cence over background, was negligible for the G31S/S32P double mutant, 
"~threefold for the $32P single mutant, and 15-fold for wild-type TSST-1 
at  optimal  binding  concentrations.  -&--,  TSST-lwt:biotin;  -~k-, 
G31S/S32P:biotin;  ~,  S32P:biotin; ~X-,  145V:biotin. 
135-139, respectively) and a class II MHC binding site within 
the NH2-terminal domain (residues  31-45).  As shown in 
Table 3, additional mutants that knocked out murine but not 
human T cell stimulation were identified. If these mutations 
are also considered, the TCR binding site consists of the central 
long oL helix (residues  127 to 150) and the NH2-terminal 
short ol helix along with its subsequent loop (residues 10-16). 
In addition, a portion of the loop between the B7  and 38 
sheets (residues 97-116) influences TCR binding. Thus, the 
TCR binding site identified by murine T cell responses pre- 
cisely overlaps with the region comprising the major groove 
in the TSST-1 molecule (10, 11). Our results  indicate that 
amino acid residues at positions 13 and/or 15, 16, 135, 137, 
and 139 appear to be the most important for TCR binding, 
because mutations in these positions almost completely abol- 
ished the stimulatory activity of TSST-1  for both murine 
and human T cells. Most notably, the residues at positions 
16, 135, and 139 are located on the protein surface (10, 11), 
and therefore these residues might directly interact with the 
TCR. On the other hand, residue 137 is buried within the 
protein and, therefore,  the effect of this mutation on TCtL 
binding would be indirect, presumably because of a distor- 
tion of local  structure. 
The MHC binding site localizes to the region in the vi- 
cinity of the NH2-terminal portion of the second 3  strand 
(Fig. 3). The five 3  strands in this region form a structure 
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Figure  3.  A ribbon  diagram of TSST-1 showing  the locations  of muta- 
tions that eliminated human T cell stimulatory activity (mutants indi- 
cated as negative in Table 3) by preventing interactions with either class 
II MHC molecules  or with the TCR VB chain. Although the 145V mu- 
tant does not completely  satisfy  these criteria, it is included in the figure 
because of its effect on MHC binding. The figure was kindly prepared 
by Dr. Douglas Ohlendorf  (University  of Minnesota, Minneapolis, MN). 
known as a B-barrel motif (10,  11). Mutations  G31S/S32P, 
which  greatly  impair  HLA-DR binding,  are  located  in  a 
solvent-exposed hydrophobic surface formed by the concave 
face of B-barrel strands  1, 2, and 3 in the NHz-terminal do- 
main.  The B-barrel motif in the NH2-terminal  domain  of 
TSST-1  is  similar  to  that  in  the corresponding  domain  of 
SEB. In SEB,  nonpolar  residues F44,  L45,  and F47 form a 
ridge that protrudes from the loop between B-strands 1 and 
2 in the NH2-terminal domain, and this ridge interacts with 
a hydrophobic depression in  the HLA-DR1 molecule (21, 
22). Mutations in SEB at F44 disrupt binding to HLA-DR 
(17). Similarly,  our study suggests that this hydrophobic re- 
gion of TSST-1 may form the MHC binding site. The I45V 
mutation (on B-strand 3) also affects MHC binding, although 
its effect is not as significant as G31S/S32P (Fig.  1 B and Fig. 
2).  In contrast  to the mutations  of G31S  and $32P,  which 
locate on the protein  surface,  the isoleucine at position 45 
is within the protein interior (10,  11). It is likely,  therefore, 
that the I45V mutation indirectly affects MHC binding by 
perturbing  the conformation  of the  hydrophobic surface. 
Binding of both TSST-1 and SEB to HLA-DK are affected 
by the same mutations in the DR a-chain,  most notably at 
residue K39 (23, 24). Although we found only a single MHC 
binding site in TSST-1, mutational analysis of SEB predicted 
two class II MHC binding sites on opposite sides of the mol- 
ecule (17). This may suggest that, whereas TSST-1 and SEB 
interact with the same region of the HLA-DR1 c~-chain, SEB 
can use a second distinct  binding  site. 
Our findings are consistent with and greatly extend previous 
studies of TSST-1 mutations that affect T  cell mitogenicity 
and toxicity (16, 25-27). For example, TSST-ovine is a natu- 
rally occurring variant that is different from TSST-1 at seven 
amino acids, including E132K and I140T. These changes have 
been predicted to be responsible for its reduced toxicity in 
rabbits (25). Furthermore,  the mutant H135A was identified 
in a previous study as lacking routine T cdl-stimulatory ac- 
tivity (27).  Our studies show that these mutations are cen- 
trally located in  the TCK binding  site. 
TSST-1  has been implicated in  "~90%  of menstruation- 
related and nearly half of nonmenstrual cases of toxic shock 
syndrome (2,  4).  In addition,  some studies have suggested 
that  TSST-1  may be  an  etiologic  agent  in  some  cases  of 
Kawasaki syndrome (20, 28), an inflammatory syndrome of 
children, although this remains controversial (29). Different 
superantigens have also been suggested as triggers for other 
autoimmune  diseases  (30-32).  The present  studies provide 
a basis for designing immunomodulatory molecules that in- 
terfere with superantigen activity and vaccines  that prevent 
the harmful effects of these potent immunostimulatory mol- 
ecules. 
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